Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Avadel Pharmaceuticals plc (NASDAQ: AVDL) was $11.06 for the day, down -0.98% from the previous closing price of $11.17. In other words, the price has decreased by -$0.98 from its previous closing price. On the day, 0.56 million shares were traded. AVDL stock price reached its highest trading level at $11.19 during the session, while it also had its lowest trading level at $10.98.
Ratios:
Our analysis of AVDL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.60 and its Current Ratio is at 2.97. In the meantime, Its Debt-to-Equity ratio is 0.49 whereas as Long-Term Debt/Eq ratio is at 0.48.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rodman & Renshaw on June 12, 2024, initiated with a Buy rating and assigned the stock a target price of $27.
On March 05, 2024, Oppenheimer reiterated its Outperform rating and also lowered its target price recommendation from $27 to $29.
Needham reiterated its Buy rating for the stock on March 05, 2024, while the target price for the stock was revised from $20 to $22.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 16 ’24 when MCHUGH THOMAS S bought 2,000 shares for $14.50 per share. The transaction valued at 29,000 led to the insider holds 80,500 shares of the business.
McCamish Mark Anthony sold 75,000 shares of AVDL for $1,089,750 on Dec 28 ’23. The Director now owns 67,025 shares after completing the transaction at $14.53 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVDL now has a Market Capitalization of 1076358144 and an Enterprise Value of 1038205504. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.71 while its Price-to-Book (P/B) ratio in mrq is 14.27. Its current Enterprise Value per Revenue stands at 7.515 whereas that against EBITDA is -16.743.
Stock Price History:
Over the past 52 weeks, AVDL has reached a high of $19.09, while it has fallen to a 52-week low of $10.41. The 50-Day Moving Average of the stock is -14.88%, while the 200-Day Moving Average is calculated to be -26.63%.
Shares Statistics:
AVDL traded an average of 1.15M shares per day over the past three months and 1305240 shares per day over the past ten days. A total of 89.83M shares are outstanding, with a floating share count of 88.18M. Insiders hold about 8.49% of the company’s shares, while institutions hold 74.70% stake in the company. Shares short for AVDL as of 1731628800 were 8814536 with a Short Ratio of 7.66, compared to 1728950400 on 10188890. Therefore, it implies a Short% of Shares Outstanding of 8814536 and a Short% of Float of 10.459999999999999.
Earnings Estimates
The dynamic stock of Avadel Pharmaceuticals plc (AVDL) is currently attracting attention from 4 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.06 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.38 and -$0.54 for the fiscal current year, implying an average EPS of -$0.49. EPS for the following year is $0.53, with 3.0 analysts recommending between $0.92 and $0.26.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 8 analysts. It ranges from a high estimate of $57.4M to a low estimate of $48.63M. As of the current estimate, Avadel Pharmaceuticals plc’s year-ago sales were $19.45MFor the next quarter, 8 analysts are estimating revenue of $58.71M. There is a high estimate of $65M for the next quarter, whereas the lowest estimate is $51.3M.
A total of 8 analysts have provided revenue estimates for AVDL’s current fiscal year. The highest revenue estimate was $176.2M, while the lowest revenue estimate was $167.33M, resulting in an average revenue estimate of $171.41M. In the same quarter a year ago, actual revenue was $27.96MBased on 8 analysts’ estimates, the company’s revenue will be $291.34M in the next fiscal year. The high estimate is $333M and the low estimate is $268.2M.
